Cambrex (CBM) vs. Its Rivals Head-To-Head Review
Cambrex (NYSE: CBM) is one of 103 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Cambrex to similar companies based on the strength of its earnings, institutional ownership, risk, valuation, profitability, analyst recommendations and dividends.
Valuation & Earnings
This table compares Cambrex and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cambrex||$490.64 million||$81.67 million||15.80|
|Cambrex Competitors||$8.17 billion||$1.09 billion||136.75|
This is a breakdown of recent ratings for Cambrex and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cambrex presently has a consensus price target of $62.33, indicating a potential upside of 29.32%. As a group, “Pharmaceuticals” companies have a potential upside of 25.19%. Given Cambrex’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Cambrex is more favorable than its rivals.
Institutional & Insider Ownership
45.4% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 2.5% of Cambrex shares are owned by company insiders. Comparatively, 11.4% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares Cambrex and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Cambrex has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500. Comparatively, Cambrex’s rivals have a beta of 38.03, indicating that their average stock price is 3,703% more volatile than the S&P 500.
Cambrex rivals beat Cambrex on 7 of the 13 factors compared.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.
Receive News & Ratings for Cambrex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Co. and related companies with MarketBeat.com's FREE daily email newsletter.